More recently, elevated expression of cyclin-dependent kinase 4 (CDK4) has been reported in patients with NSCLC progressed after dabrafenib-trametinib therapy [85]; however, the precise mechanisms underlying resistance acquisition have yet to be clarified. The gene discussed is CDK4; the disease is non-small cell lung carcinoma.